| Old Articles: <Older 4821-4830 Newer> |
|---|
 |
The Motley Fool
May 2, 2008
Brian Orelli |
Sepracor Diversifies to Sleep Better With its two top drugs in decline, diversification was the only answer for Sepracor.   |
The Motley Fool
May 2, 2008
Steven Renaldi |
Cardinal Health Gets Its Nest in Order Share price rises as investors hope the company is beginning to put some of its troubles behind it. |
The Motley Fool
May 1, 2008
Brian Lawler |
Soliris Brightens Alexion's Quarter Alexion Pharmaceuticals' lone drug posts gargantuan growth. |
The Motley Fool
May 1, 2008
Brian Lawler |
Glaxo's Global Growth Gambit The pharmaceutical's new CEO has changes in mind. |
Chemistry World
May 2008
Derek Lowe |
In the pipeline The controversy over cholesterol drug Vytorin has been going on for months. Surveying the wreckage, my first thought is: what a terrible shame the whole affair is. |
The Motley Fool
April 30, 2008
Brian Lawler |
Pfizer Protects Profitable Patent The courts uphold a key patent on Pfizer's top drug. |
The Motley Fool
April 30, 2008
Brian Lawler |
The Start of a New Endo The drugmaker marks its first quarter under new management. |
The Motley Fool
April 30, 2008
Brian Lawler |
Idenix Aims for a Comeback This drugmaker may be down, but it's not yet out. |
The Motley Fool
April 30, 2008
Brian Lawler |
Alexza Advances 2 More Drugs The pharmaceutical company's compounds keep zipping through clinical trials. |
The Motley Fool
April 30, 2008
Brian Lawler |
A Dominating Danish Drugmaker Novo Nordisk turns in solid first-quarter financial numbers. |
| <Older 4821-4830 Newer> Return to current articles. |
